In a major development with regard to the coronavirus pandemic, the U.S govt. has made a unilateral and highly dominant move🤨.
It has bought nearly the entire world’s supply😳 of remdesivir, one of only two drugs which are known to treat Covid-19.
It is exclusively manufactured🏭 by pharmaceutical giant Gilead.
More about Remdesivir
Remdesivir is an anti-viral medicine💊 that has been used in treating Ebola.
It attacks an enzyme that a virus🦠 needs in order to replicate inside human cells.
Remdesivir has been found to reduce recovery time from 15 to 11 days for those Covid patients😷, which have the most severe infections.
However, this effect has ☝️not been observed in patients with moderate symptoms.
Why U.S took all of it?
At present, the US is easily the topmost Covid impacted country😩 in the world.
Currently, it has over 2.6 million confirmed cases and has recorded more than 1.27 lakh COVID-related deaths😢.
In view of this, the Trump administration has bought more than 500,000 doses of remdesivir, which is equivalent to Gilead’s total production for July and 90% for the months of August and September🗓️.
Significantly, this move has left Gilead with no stocks until October🤷♂️ for the rest of the world including other developed countries.
Comes at a price
A typical five-day treatment course👩🏻🔬 with Remdesivir will come at around $3,100 (Rs. 2.3 lakhs) per patient in the developed nations.
Meanwhile, Gilead has made an agreement🤝 with 5 generic pharma companies of India and Pakistan under which the drug would be produced and supplied at around $600👍 to 127 poor or middle-income countries.